94 related articles for article (PubMed ID: 19428092)
1. Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines.
Nishikawa T; Kohjimoto Y; Nishihata M; Ebisuno S; Hara I
Urology; 2009 Dec; 74(6):1370-6. PubMed ID: 19428092
[TBL] [Abstract][Full Text] [Related]
2. The cytotoxic effect of fleroxacin and ciprofloxacin on transitional cell carcinoma in vitro.
Ebisuno S; Inagaki T; Kohjimoto Y; Ohkawa T
Cancer; 1997 Dec; 80(12):2263-7. PubMed ID: 9404703
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effects of the aqueous extract of Magnolia officinalis on the responses of human urinary bladder cancer 5637 cells in vitro and mouse urinary bladder tumors induced by N-Butyl-N-(4-hydroxybutyl) nitrosamine in vivo.
Lee SJ; Cho YH; Park K; Kim EJ; Kang BS; Jung KH; Kim CH; Kim WJ; Moon SK
Phytother Res; 2009 Jan; 23(1):20-7. PubMed ID: 19048611
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo.
Kase S; Kubota T; Watanabe M; Furukawa T; Tanino H; Ishibiki K; Teramoto T; Kitajima M
Anticancer Res; 1993; 13(2):369-73. PubMed ID: 8517649
[TBL] [Abstract][Full Text] [Related]
6. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo.
Pederson LC; Buchsbaum DJ; Vickers SM; Kancharla SR; Mayo MS; Curiel DT; Stackhouse MA
Cancer Res; 1997 Oct; 57(19):4325-32. PubMed ID: 9331094
[TBL] [Abstract][Full Text] [Related]
7. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
[TBL] [Abstract][Full Text] [Related]
8. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
9. Effects of the combination of hyperbaric oxygen and 5-fluorouracil on proliferation and metastasis of human nasopharyngeal carcinoma CNE-2Z cells.
Peng ZR; Zhong WH; Liu J; Xiao PT
Undersea Hyperb Med; 2010; 37(3):141-50. PubMed ID: 20568543
[TBL] [Abstract][Full Text] [Related]
10. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
11. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of common antibiotics against superficial bladder cancer.
Kamat AM; Lamm DL
Urology; 2004 Mar; 63(3):457-60. PubMed ID: 15028437
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
Kojiro S; Yano H; Ogasawara S; Momosaki S; Takemoto Y; Nishida N; Kojiro M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):129-37. PubMed ID: 16706824
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergism of vinorelbine and 5-fluorouracil/UFT against non-small cell lung cancer.
Matsumoto S; Igishi T; Hashimoto K; Kodani M; Shigeoka Y; Nakanishi H; Touge H; Kurai J; Makino H; Takeda K; Yasuda K; Hitsuda Y; Shimizu E
Int J Oncol; 2004 Nov; 25(5):1311-8. PubMed ID: 15492820
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.
Fischel JL; Etienne MC; Spector T; Formento P; Renée N; Milano G
Clin Cancer Res; 1995 Sep; 1(9):991-6. PubMed ID: 9816071
[TBL] [Abstract][Full Text] [Related]
16. The effect of calmodulin antagonist berbaminederivative-EBB on hepatoma in vitro and in vivo.
Liu J; Qi S; Zhu H; Zhang J; Li Z; Wang T
Chin Med J (Engl); 2002 May; 115(5):759-62. PubMed ID: 12133551
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin: a potential chemopreventive agent in bladder cancer.
Kamat AM; Nelkin GM
Urology; 2005 Dec; 66(6):1209-12. PubMed ID: 16360444
[TBL] [Abstract][Full Text] [Related]
18. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
Kim R; Tanabe K; Inoue H; Toge T
Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
[TBL] [Abstract][Full Text] [Related]
19. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
20. Significance of 5-fluorouracil-related enzyme activities in predicting sensitivity to 5-fluorouracil in bladder carcinoma.
Furuse H; Hirano Y; Harada M; Ming LH; Aoki T; Kurita Y; Mugiya S; Ushiyama T; Ozono S
Anticancer Res; 2009 Apr; 29(4):1001-8. PubMed ID: 19414338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
